Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21503575 | 1.00 | ALDH1A1 (0.44) | ALDH1A1HPGDHTR7AOC3HTT | |
| SCHEMBL782013 | 1.00 | ALDH1A1 (0.44) | ALDH1A1HPGDHTR7AOC3HTT | |
| SCHEMBL13792137 | 0.94 | ALDH1A1 (0.41) | ALDH1A1HPGDHTT | |
| SCHEMBL9746668 | 0.88 | RIPK1 (0.43) | — | |
| SCHEMBL15870930 | 0.87 | ALDH1A1 (0.47) | ALDH1A1HPGDHTR7AOC3HTT | |
| SCHEMBL9278852 | 0.87 | HTR7 (0.40) | ALDH1A1HPGDHTR7SLC6A2SLC6A3 | |
| SCHEMBL9232425 | 0.87 | HTR7 (0.40) | ALDH1A1HPGDHTR7SLC6A2SLC6A3 | |
| SCHEMBL22649183 | 0.85 | HTR7 (0.39) | ALDH1A1HPGDHTR7SLC6A2SLC6A3 | |
| SCHEMBL8217828 | 0.85 | HTR7 (0.39) | ALDH1A1HPGDHTR7SLC6A2SLC6A3 | |
| SCHEMBL21536775 | 0.84 | PSMD14 (0.41) | ALDH1A1HPGDHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059826-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-07-13 | — | — | US | disclosed |
| US-20190322673-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2019-10-24 | — | — | US | disclosed |
| EP-1569917-B1 | PYRAZINE-BASED TUBULIN INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2016-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322673-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | ALDH1A1 569/4885HPGD 34/4885HTR7 2956/4885 |
| US-11059826-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | ALDH1A1 569/4885HPGD 34/4885HTR7 2956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.